AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2017
Jun 16, 2017
31801_dirs_2017-06-16_ec4ac888-2240-4864-bdf2-85ea889c011b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2017-06-15
Reporting Person: Cavanaugh Sarah (SVP of Corp. Affairs & Admin.)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, par value $0.001 per share | 4760 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $4.71 | 2022-08-15 | Common Stock (7500) | Direct | |
| Employee Stock Option (right to buy) | $16.36 | 2023-07-01 | Common Stock (20000) | Direct | |
| Employee Stock Option (right to buy) | $13.45 | 2024-06-04 | Common Stock (25000) | Direct | |
| Employee Stock Option (right to buy) | $25.41 | 2025-06-10 | Common Stock (30000) | Direct | |
| Employee Stock Option (right to buy) | $4.72 | 2026-06-08 | Common Stock (22000) | Direct |
Footnotes
F1: The option became exercisable as to 25% of the shares on 8/15/2013 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
F2: The option became exercisable as to 25% of the shares on 7/1/2014 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters.
F3: The option became exercisable as to 25% of the shares on 6/4/2015 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters.
F4: The option became exercisable as to 25% of the shares on 6/10/2016 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters.
F5: The option became exercisable as to 25% of the shares on 6/8/2017 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.